DiaMedica Therapeutics Inc. stock is up 3.61% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 11 February’s closed higher than January.
DiaMedica Therapeutics Inc. develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein. DM199 is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!